Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
November 6, 2023
This article is featured on another website.
Go to article
May 13, 2025
Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.
May 13, 2025
Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.